SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems
9.9.2019 09:55:00 EEST | Business Wire | Press release
SES today announced it will provide dedicated, private network connectivity from any vessel, airplane, enterprise, energy or government site in the world to Microsoft Azure via its unique multi-orbit satellite systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190908005042/en/
SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems (Photo: Business Wire)
As a partner of Azure ExpressRoute, SES will provide global reach and fibre-like high-performance to Azure customers via its complete portfolio of Geostationary Earth Orbit (GEO) satellites, Medium Earth Orbit (MEO) O3b constellation, global gateway network, and core terrestrial network infrastructure around the world. SES will offer Azure customers opportunities to leverage its satellite-enabled managed services to connect locations and sites in rural, remote and underserved locations, as well as vessels and airplanes out at sea and in the skies that previously did not have access to cloud services.
In addition to its global fleet of over 50 GEO satellites, SES also delivers managed data services over its proven O3b MEO satellite system, the only successful non-geostationary orbit (NGSO) broadband constellation. SES’s 20 O3b satellites comprise the only operational system today that can deliver fibre-equivalent, MEF-certified data connectivity services, and certified cloud connectivity services. The systems’ intelligent GEO- and MEO- orbit resilience that facilitate edge compute capabilities are key enablers in the seamless integration of high-performance satellite connectivity into Microsoft’s and their customers’ sites.
In addition, Azure customers also will be able to tap into SES’s groundbreaking next-generation MEO communications system, O3b mPOWER. Launching in 2021, O3b mPOWER will deliver ten times the throughput of the existing O3b constellation with unprecedented flexibility and dynamic control to help drive global cloud adoption everywhere.
“We believe that the economic and productivity benefits of the cloud should be easily available to all enterprise, maritime and aeronautical customers as well as government organisations, regardless of location. Now, as a Microsoft Azure ExpressRoute connectivity partner, we are expanding our strategic collaboration with Microsoft and extending intelligent cloud and edge services from Azure to the most underserved end points on the planet,” said JP Hemingway, CEO of SES Networks. “As the only satellite network services provider to operate a global, multi-orbit fleet utilising an extensive fleet of GEO and MEO satellites, SES stands ready to help Azure customers connect to any site at cloud scale, supporting critical enterprise workloads and offering an end-to-end network solution for emerging AI, IoT, video content services, and future applications to come.”
Ross Ortega, Partner, Product Manager of Azure Networking, Microsoft Corp. said, “We are collaborating with SES across a range of initiatives to build upon their expertise in satellite communications and increase connectivity to critical services and applications for customers in remote and underserved areas. This new collaboration between SES and Microsoft Azure Express Route further enables us to bring Azure to any business or government site.”
SES also announced today an expanded collaboration with Microsoft to benefit from Azure’s extensive cloud and AI capabilities to deliver one of the first broadcast-grade cloud services for media delivery. This builds on the broader strategic work between SES and Microsoft, as well as their shared common vision to reach everyone with intelligent cloud, media and network solutions.
More information on Azure ExpressRoute Data Sheet available here.
Follow us on:
Social Media
Blog
Media Library
About SES
SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 355 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. SES Video delivers a full suite of innovative end-to-end value-added services for both linear and digital distribution, and includes the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190908005042/en/
Contact information
For further information:
Suzanne Ong
Public Relations
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom